RankAlpha logo
Back to Rankings

ELTX

Elicio TherapeuticsF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The bullish read is that June 15 may have reset expectations aggressively enough that even a damaged thesis still has optionality: the company preserved a narrower R0-focused Phase 3 story, cited biologic activity, and still has potential partnering or regulatory paths instead of a full program stop.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.7.
What can break
AMPLIFY-7P failed its pre-specified primary DFS endpoint in the intent-to-treat population, which materially weakens the original lead-program thesis.
Momentum
1
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.80 · Bull $7.00 · Bear $1.20
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $19.10
Why
Momentum1 · Δ7d -0.0
Value41 · Δ7d +0.0
Sentiment55 · Δ7d +7.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
1
26% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
55
34% active weight
Current posture
7d trendImproving
Δ7d
+7.7
Δ21d
+21.7
Why this grade

Composite grade F. Momentum 1.2 / Value 41.1 / Sentiment 55.0

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$71.34M
Beta
-
Shares Out
23.47M
P/E (TTM) · Derived
-1.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.35
Rev YoY
-100.0%
EPS YoY
-25.0%
Gross Margin
+62.3%
Op Margin
-
Net Debt
-$4.05M
Current Ratio
2.24
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology